News GSK taps into UK health data for dementia study GSK joins with two UK research organisations to explore a possible link between its shingles vaccine Shingrix and a reduced risk of dementia.
News GSK bows to Trump pressure and pauses diversity policies GSK has joined a lengthening list of companies that have paused diversity, equity, and inclusion (DEI) targets under pressure from US President Trump.
News FDA sets June date for Gilead's twice-yearly HIV PrEP Gilead's already dominant position in HIV PrEP could be extended if the FDA approves a new twice-yearly injectable product later this year.
News GSK gets ready for its next big vaccine launch GSK joins arch-rival Pfizer in the market for five-in-one meningococcal vaccines with FDA approval for Penmenvy, a top launch prospect for 2025.
News GSK rides out vaccine sales weakness with cancer, HIV gains Despite a steep fall-off in sales of RSV vaccine Arexvy last year, GSK has raised its long-term sales forecast to £40 billion in 2031.
News Stopwatch starts on reviews of GSK's long-acting asthma drug Regulators have started reviews of GSK's depemokimab, aiming to become the first drug for asthma that can be dosed twice a year.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.